We are developing therapeutics to cure Alzheimer' s. We anticipate to partner with big pharmaceuticals to conduct Phase iii and exit at this stage ( three years). Company received 3 M grant in 2016 to develop the product and may receive additional 3 M in 2017 grant to complete the Phase 1 clinical studies.
Exit might provide 10-20 fold upside for the investors in three years.